MEI Pharma, Inc. (NASDAQ:MEIP)

CAPS Rating: 1 out of 5

A development stage company, engaged in the clinical development of the anti-cancer drug phenoxodiol.

Recs

1
Player Avatar tharlow (64.51) Submitted: 11/9/2007 12:05:47 AM : Outperform Start Price: $18.00 MEIP Score: -86.93

This company has a portfolio of next-generation cancer drugs with blockbuster potential. Look no further for the next Genentech.

Featured Broker Partners


Advertisement